Barry A. Labinger

Barry A. Labinger is currently Chief Executive Officer at Flashpoint Therapeutics, Inc. since 2025, Chief Executive Officer at Gilboa Therapeutics Ltd. since 2022, and President at Checkmate Pharmaceuticals, Inc. Formerly, Mr. Labinger was President, Chief Executive Officer & Director at Checkmate Pharmaceuticals, Inc. from 2018 to 2021; President & Chief Executive Officer at Biothera Pharmaceuticals, Inc. (Delaware) from 2015 to 2018; Senior Director-Diabetes Marketing at Bristol Myers Squibb Co. from 1997 to 2000; Director at Anadys Pharmaceuticals, Inc. in 2011; President, Chief Executive Director & Director at Biothera, Inc.; SVP, VP-Marketing & GM-Commercial Operations at Immunex Corp.
from 2000 to 2002; Divisional Vice President at 3M Co. from 2002 to 2005; Chief Commercial Officer & Executive VP at Human Genome Sciences, Inc. from 2010 to 2012; and Executive VP & President-Biosciences Division at Emergent BioSolutions, Inc. from 2013 to 2016.
Education includes undergraduate studies at Northwestern University and an MBA from Kellogg School of Management.